亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

B32-10 Twice-yearly Depemokimab Is Well Tolerated Over 2 Years in Patients With Type 2 Asthma: An Integrated Safety Analysis of the Phase III SWIFT-1/-2 and the Open-label Extension AGILE Studies

作者
ARNAUD AB BOURDIN,Daniel J Jackson,Diana Jarreta,C-Q Zhu,T Adeloye,A Platt,Peter Hugo Howarth,Daniel J Jackson
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:212 (Supplement_1) 被引量:1
标识
DOI:10.1093/ajrccm/aamag162.450
摘要

Abstract Rationale Depemokimab is the first ultra-long-acting biologic, with enhanced interleukin-5 binding affinity, high potency, and extended half-life, enabling twice-yearly dosing in asthma. The safety and efficacy of depemokimab over 52 weeks in patients with type 2 asthma have been demonstrated in the Phase III SWIFT-1/-2 studies. Here, we assess the long-term safety of depemokimab over 2 years in an integrated post hoc analysis of the SWIFT-1/-2 and AGILE open-label extension (OLE) studies in patients with type 2 asthma. Methods Eligible adults with type 2 asthma characterized by blood eosinophil counts received subcutaneous depemokimab 100 mg or placebo at Weeks 0 and 26, up to 52 weeks, in SWIFT-1/-2. After completing SWIFT-1/-2, patients were invited to join the multicenter, single-arm AGILE OLE study, where all patients received depemokimab 100 mg for an additional 52 weeks, for a total follow-up period of 104 weeks. Here we present safety results, including adverse events (AE), serious AEs (SAE), and AEs of special interest (AESI; including allergic or other systemic reactions, and injection-site reactions), that were analyzed descriptively in patients who received depemokimab for the full 2-year period. Results Of the 502 patients randomized to receive depemokimab in SWIFT-1/-2, 419 (83%) patients entered the OLE and continued to receive depemokimab. Over the 2-year period, on-treatment AEs were reported in 86% of patients (Figure), of which COVID-19 (25%), nasopharyngitis (23%), and upper respiratory tract infection (16%) were most common. Treatment-related AEs (per investigator assessment) occurred in 6% of patients, with headache (1%), injection-site reaction (<1%), and leukopenia (<1%) being the most commonly reported. AEs leading to discontinuation or dose interruption were infrequent (both <1%). SAEs occurred in 13% of patients, of which asthma (3%) was the only SAE to occur in ≥ 1% of patients. No treatment-related SAEs (per investigator assessment) or fatal SAEs occurred during the study. AESIs were infrequent (4%); when assessed by system organ class, nervous system disorders (2%), general disorders and administration site conditions (1%), and skin and subcutaneous tissue disorders (<1%) were most common, and no single event occurred in ≥ 1% of patients. Conclusions Depemokimab was well tolerated over the 2-year period, with no significant safety concerns identified. The long-term safety profile of depemokimab was consistent with Phase III programs for asthma and chronic rhinosinusitis with nasal polyps, supporting the risk-benefit profile of depemokimab. This abstract is funded by: GSK (SWIFT-1/-2: 206713/213744, NCT04719832/NCT04718103; AGILE: 212895/NCT05243680).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
foden完成签到,获得积分10
4秒前
xinran完成签到,获得积分10
9秒前
温暖的帆布鞋完成签到,获得积分10
12秒前
yli130完成签到,获得积分10
13秒前
13秒前
19秒前
Sarahminn发布了新的文献求助10
20秒前
22秒前
俏皮的灵发布了新的文献求助10
23秒前
机灵的沂完成签到,获得积分10
35秒前
奔跑的应助被虚心的灵寒采纳,获得10
36秒前
奔跑的应助被虚心的灵寒采纳,获得10
36秒前
欢呼的兰完成签到,获得积分10
39秒前
华仔的应助被lmn采纳,获得10
43秒前
酒酿是也完成签到 ,获得积分10
43秒前
满意的楷瑞完成签到,获得积分10
45秒前
顺利的水瑶完成签到 ,获得积分10
47秒前
50秒前
我是老大的应助被科研通管家采纳,获得10
50秒前
彭于晏的应助被科研通管家采纳,获得10
50秒前
50秒前
52秒前
慕青的应助被肖可声采纳,获得10
52秒前
田様的应助被重要白亦采纳,获得10
54秒前
科研通AI6.2的应助被Jeff采纳,获得20
55秒前
科研通AI6.3的应助被Jeff采纳,获得50
55秒前
烟花的应助被俏皮的灵采纳,获得10
56秒前
lmn发布了新的文献求助10
57秒前
1分钟前
Maestro_S的应助被Kaikai采纳,获得10
1分钟前
1分钟前
肖可声完成签到,获得积分10
1分钟前
mino完成签到 ,获得积分10
1分钟前
1分钟前
肖可声发布了新的文献求助10
1分钟前
铃木完成签到,获得积分10
1分钟前
重要白亦发布了新的文献求助10
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565447
关于积分的说明 21780029
捐赠科研通 7764817
什么是DOI,文献DOI怎么找? 3431496
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476571